N2703 in Adipose-Neural Cardiac Signaling

2026-09-14

N2703 provides a controlled small-molecule perturbation strategy for studying neuro-adipose and cardiac signaling without assuming a predefined molecular target. This workflow combines solvent-aware handling, causal controls, and electrophysiology-oriented readouts to distinguish pathway modulation from nonspecific toxicity.

Diclofenac in Intestinal Organoid Assays

2026-09-14

Learn how to use Diclofenac as a mechanistic COX probe in hiPSC-derived intestinal organoids while preserving pharmacokinetic context. This workflow combines formulation control, 2D epithelial readouts, and troubleshooting for more reproducible inflammation and drug-metabolism studies.

Sabutoclax: Reading Apoptosis Data Correctly

2026-09-13

Sabutoclax is a pan-Bcl-2 inhibitor with broad anti-apoptotic protein activity and strong preclinical anticancer effects. This article explains how to distinguish cytostatic responses from genuine apoptosis induction in cancer cells when designing and interpreting Sabutoclax assays.

Sadoamides A and B: New Proteasome Inhibitors

2026-09-12

The reference study identifies sadoamides A and B, unusual aromatic tripeptides from Streptomyces sp. YNK18, as proteasome inhibitors that connect microbial natural-product chemistry with apoptosis regulation. Its integrated spectroscopic, enzymatic, and cellular experiments show that sadoamide A stabilizes MCL1 and protects cells from apoptosis-inducing stimuli, providing a useful framework for studying ubiquitin–proteasome system control of cell fate.

SAR405: Selective Vps34 Inhibitor

2026-09-12

SAR405 is a selective ATP-competitive Vps34 inhibitor for mechanistic studies of autophagy inhibition and vesicle trafficking modulation. Its nanomolar biochemical potency, pathway-level readouts, and defined solvent profile support controlled cellular experiments rather than direct extrapolation to clinical efficacy.

In Vitro Drug Response: Growth Inhibition vs Cell Death

2026-09-11

Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a more resolved framework for separating proliferative arrest from actual cell killing, improving interpretation of drug sensitivity studies and experimental design.

Blue Light, EGFR Signaling, and Skin Barrier Damage

2026-09-11

A 2026 Journal of Investigative Dermatology study combines controlled human exposure, mouse validation, imaging, and barrier-function measurements to show that repeated blue light irradiation produces persistent skin barrier impairment. Its EGFR/ERK/c-Jun framework connects visible-light exposure with epidermal remodeling, pigmentation, and transepidermal water loss, while also defining important limits for mechanistic and translational interpretation.

EDC.HCl: Practical Coupling Workflow

2026-09-10

EDC.HCl is a water-soluble carbodiimide used to activate carboxyl groups for amide bond formation with primary amines in peptide synthesis, bioconjugation, and related in vitro workflows. This guide covers practical setup, storage, and troubleshooting; the reagent should not be treated as validated for in vivo or clinical use because supporting data are unavailable.

Phebestin: Aminopeptidase-Targeted Antimalarial Evidence

2026-09-10

The reference study identifies phebestin, a bestatin-related aminopeptidase inhibitor, as a nanomolar antiplasmodial candidate active against both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. Its integrated parasite-stage, washout, computational, cytotoxicity, and mouse experiments provide a useful framework for evaluating aminopeptidase-directed malaria drug leads.

Sex Differences in Angiotensin II Hypertension

2026-09-09

Xue, Pamidimukkala, and Hay used telemetry in conscious mice to show that chronic angiotensin II caused a substantially larger blood-pressure increase in males than in females. Gonadectomy, baroreflex testing, and ganglionic blockade further linked this divergence to sex-dependent hormonal and autonomic regulation rather than baseline blood pressure alone.

Hyaluronic Acid Sodium Salt in siRNA Workflows

2026-09-09

Hyaluronic acid sodium salt connects extracellular-matrix modeling with HA-coated siRNA delivery, enabling practical studies of immune-cell trafficking, inflammation, and tissue injury. This guide translates the TDRD9 nanoparticle study into assay-ready formulation, validation, and troubleshooting strategies while separating reported findings from proposed starting conditions.

SAG Workflow for Hedgehog Pathway Studies

2026-09-08

SAG provides a controllable Smoothened receptor agonist workflow for pathway activation, rescue experiments, neurobiology, and developmental models. This guide connects practical dosing and assay design with a medulloblastoma study that used SAG challenge to localize compound activity at the Smoothened level.

E-4031: Practical hERG Blocker Workflows

2026-09-07

E-4031 provides a nanomolar, mechanism-focused way to interrogate hERG/IKr-dependent repolarization, from patch-clamp current assays to QT and arrhythmia models. This guide combines reproducible handling, concentration planning, translational assay design, and troubleshooting for cardiac electrophysiology research.

Artesunate: From IC50 to Cell-Killing Insight

2026-09-07

Artesunate is more than a low-micromolar viability hit: this guide explains how to distinguish growth inhibition from actual cell killing when studying an artemisinin derivative. It connects the B3662 product profile with a dissertation-backed framework for small cell lung carcinoma research and mechanistic validation.

Cholesterol Hinders Lipid Nanoparticle Trafficking

2026-09-05